Depression
Conditions
Keywords
major depression, antidepressant, quality of life, anxiety
Brief summary
The investigators hypothesize that Rellidep will be effective in improving the symptoms of major depression. The available evidence strongly suggests that Rellidep contains a mood altering ingredient or ingredients. This open-label, non-randomized study sets out to validate its potential antidepressant activity.The study will include secondary aims of evaluating the effect of Rellidep on reducing symptoms of anxiety, a common symptom associated symptom of depression and improving quality of life. About twenty-five patients with major depressive disorder will be assigned to open-label Rellidep (2000 mg/day) for a period of 8 weeks. All patients will be assessed by various measures of global improvement, depression, quality of life, sexual experience, anxiety and measures of side effects as well as standard laboratory tests.
Interventions
DRUGRellidep
2000 mg P.O. daily for 8 weeks
Sponsors
Mount Sinai Hospital, Canada
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No
Inclusion criteria
* Signed written informed consent obtained. * Males/Females 20-65 years of age who require a new or a new change in their medication treatment for diagnosed major depression. * A clinical diagnosis fulfilling DSM-IVTR criteria for Major Depressive Disorder, single episode or recurrent. * 17-Item Hamilton Depression Rating Scale (HAMD 17-item) total score at baseline of 18 or higher
Exclusion criteria
* Clinical diagnosis of depression other than DSM-IVTR Major Depressive Disorder (single episode/recurrent, e.g. chronic depression and/or refractory depression are excluded). * Judged to be at significant risk for suicide or having a history suggesting significant current potential for self harm. * Antidepressant medication (other than the index antidepressant). * Women who are pregnant or breast-feeding or intending to become pregnant in the next 12 months. * Clinically significant organ system diseases, e.g. cardiovascular, hepatic, renal, endocrine, gastrointestinal, metabolic, or other systemic diseases. * Course of electroconvulsive therapy (ECT) during the observational period. * Suffer from a major neurological condition (i.e., Parkinson's disease, Huntington's disease), cerebrovascular disease (i.e., stroke), metabolic conditions (i.e., Vitamin B12 deficiency), autoimmune conditions (i.e., systematic lupus erythematosus), viral or other infections (i.e., hepatitis, mononucleosis, human immunodeficiency), and cancer. * Current diagnosis of Schizophrenia or other psychotic disorders (including Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, brief psychotic disorders, psychotic disorder due to general medical condition, substance induced psychotic, psychotic disorder not otherwise specified) as defined in the DSM-IV. * (Sub) clinical hypo/hyper thyroidism (e.g. elevated TSH).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 50% improvement on Hamilton Depression Rating Scale-17 at 8 weeks | 8 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Montgomery Asberg Depression Rating Scale (MADRS) at 8 weeks | 8 weeks |
| Medical Outcomes Study Short-Form 36 (SF-36)at 8 weeks | 8 weeks |
| Clinical Global Impression-Severity and Improvement | 8 weeks |
| Hamilton rating scale for Anxiety (HAM-A)at 8 weeks | 8 weeks |
| UKU | 8 weeks |
| Beck Depression Inventory Scale (BDI) a t 8 weeks | 8 weeks |
Countries
Canada
Outcome results
None listed